News Related to Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Related coverage linked through entity extraction aliases.

Merck/Gilead Discontinue Lung Cancer Trial as Pfizer, Roivant Report Pipeline Updates

Jun 09, 2026

Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.

Gossamer Bio's Seralutinib Misses Primary Endpoint in Phase 3 PAH Trial

Feb 23, 2026

Gossamer Bio's seralutinib narrowly missed its primary endpoint in the Phase 3 PROSERA study for pulmonary arterial hypertension, achieving a p-value of 0.0320 versus the prespecified threshold of 0.025, though showing stronger results in intermediate- and high-risk patients.